#Israel #CollPlant #rhCollagen #Rehovot #dermal filler

CollPlant Biotechnologies Achieves Key Patent Milestone in South Korea

CollPlant Biotechnologies, known for its pioneering work in regenerative and aesthetic medicine, has secured a crucial patent allowance from the Korean Patent Office. This patent pertains to their innovative photocurable dermal filler technology, moving the company closer to revolutionizing the aesthetic market. The announcement, made on February 26, 2026, marks a pivotal moment for CollPlant as it expands its intellectual property portfolio in one of the world’s most lucrative markets for aesthetic treatments.

The patent covers a polymerizable solution designed for tissue augmentation. This cutting-edge technology utilizes a method where the dermal filler is injected into tissue and then solidifies in response to external light activation. Such innovation not only underscores the advanced nature of CollPlant’s proprietary rhCollagen (recombinant human collagen) platform but also sets a new standard for safety and effectiveness in cosmetic procedures.

Yehiel Tal, the CEO of CollPlant, emphasizes the strategic importance of this patent allowance. He stated, "This achievement represents another crucial milestone in executing our strategy to broaden the applications of our rhCollagen technology in high-value aesthetic markets. South Korea's reputation in aesthetic medicine makes it an essential location for our market penetration."

The photocurable dermal filler platform not only aims to lift and enhance skin contours but is also designed to facilitate structural tissue restoration. By leveraging light-activated properties, the filler creates a supportive framework within the tissue that promotes lasting contour stability. This unique combination of functionalities positions CollPlant’s product at the forefront of the injectable soft-tissue filler market, projected to surpass $6 billion in value by 2026.

Moreover, the formulation of this dermal filler integrates chemically modified rhCollagen along with hyaluronic acid elements, ensuring it possesses the necessary viscosity to be administered through thin surgical needles while allowing flexibility for post-injection shaping as needed. The structure strengthens over time, enhancing tissue integration and durability.

CollPlant’s recent accomplishment aligns with its broader strategy to solidify its foothold in the international market. Notably, the Korean patent allowance follows the recent grant of a similar patent in Japan covering the photocurable dermal filler kit and related compositions. It reveals CollPlant's commitment to global expansion and innovation in aesthetic medicine, backed by its patented technologies now recognized in major markets across the United States, Europe, China, Brazil, Australia, and Israel.

In 2021, CollPlant entered into a significant development and commercialization agreement for dermal fillers with Allergan, a subsidiary of AbbVie that leads the global dermal filler market. This partnership highlights CollPlant's strengths in bridging advanced scientific research with commercial opportunities in the aesthetic space.

As the industry progresses towards more effective and safer cosmetic procedures, innovations like those from CollPlant position the company to not only participate but also lead in the future of aesthetic medicine. With intellectual property protections extending until 2039, CollPlant stands ready to capitalize on its advancements and strategically navigate the competitive landscape.

In essence, CollPlant Biotechnologies' recent patent allowance in South Korea serves as a testament to its innovative spirit and commitment to enhancing patient outcomes in aesthetic treatments. The integration of rhCollagen in their product suite reflects a transformative approach, merging biotechnology with beauty, and it reveals just how crucial intellectual property is in maintaining a competitive edge in this rapidly evolving market. For more information on CollPlant and its pioneering work, you can visit CollPlant's official website.